Φορτώνει......
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
BACKGROUND: Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS: Here we describe the first clinical study with BAN2401. Safety...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Alzheimers Res Ther |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4822297/ https://ncbi.nlm.nih.gov/pubmed/27048170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-016-0181-2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|